Recon: Moderna completes enrollment in Phase 3 COVID vaccine study; Dr Reddy’s hit by cyberattack

• An angry Azar floats plans to oust FDA’s Hahn (Politico)
• Moderna completes enrollment in large COVID-19 vaccine study (Reuters)
• Roche, Atea team up on potential COVID-19 pill (Reuters)
• US likely to have enough COVID-19 vaccines for all vulnerable Americans by year end: official (Reuters)
• Why the US doesn’t have an at-home coronavirus test yet (Politico)
• The FDA Wanted to Ban Some Hair Straighteners. It Never Happened. (NYTimes)
• Trump Promised Seniors Drug Discount Cards. They May Be Illegal. (NYTimes)

• Deceased AstraZeneca Trial Volunteer Didn’t Receive Vaccine (Bloomberg) (Reuters)
• Study finds AstraZeneca's COVID-19 vaccine follows genetic instructions (Reuters)
• In WHO overhaul push, EU urges changes to handling of pandemics (Reuters)
• China wants to take active role in WHO reform process: foreign ministry (Reuters)
• Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan (Reuters)
• South Korea sticks to flu vaccine plan despite safety fears after 25 die (Reuters)
• Britain authorises temporary use of flu vaccine to help meet demand (Reuters)
• Afreximbank ready to raise up to $5 bln for COVID-19 vaccines for Africa: CDC head (Reuters)
• India's Dr Reddy's isolates data center services after cyberattack (Reuters) (Economic Times)

• CDC broadens definition of who's at risk of getting coronavirus (Politico)
• How much will a Covid-19 vaccine cost? (FT)
• Wikipedia and WHO Join to Combat Covid Misinformation (NYTimes)
• Democrats want to fire Warp Speed’s Moncef Slaoui and overhaul the program. But if Biden wins, should he? (STAT)
• As Covid-19 intensifies, shortages of staple drugs may grow worse (STAT)
• How Will The U.S. Distribute COVID-19 Antibody Drugs If They Get FDA Approval? (NPR)
• Britain partners with Oxford firm to assess coronavirus vaccine T cell responses (Reuters)
• The Coronavirus Has Claimed 2.5 Million Years of Potential Life in the US, Study Finds (NYTimes)

• New rare disease gene therapy startup recruits former Sarepta executive as CEO (STAT) (BioPharmaDive)
• Californians Asked to Pony Up for Stem Cell Research — Again (KHN)
• European cities plead for more flu shots as winter looms, pandemic rages (Reuters)
• 25 Drugs, Drug Classes Added to FDA's Safety Signal List (Medscape)
• Compulsory Licensing for Pharmaceuticals in the EU: A Reality Check (Harvard Bill of Health)
• 10th ESVAC report shows continued decrease in sales of veterinary antibiotics (EMA)
• NICE recommends MSD's Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (Pharmafile)
• Gilead's Biktarvy proves non-inferior to standard care for HIV in Black and African American patients (Pharmafile)
• Covid-19 is pushing pharma to the cloud — and convincing the industry of its value (STAT)
• With lumasiran on the FDA's doorstep, Alnylam reads out new PhIII data in PH1 (Endpoints)
• Pfizer scoops up an antibiotic in rare M&A deal, bagging a virtual startup operating on a shoestring budget (Endpoints)
• FDA blasts another U.S. drugmaker for faulty quality controls on now-recalled thyroid meds (Fierce)
• Aurobindo Pharma arm's New Jersey unit gets warning letter from USFDA (Economic Times)
• Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech (Endpoints)
• Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases (Endpoints)
• Peter Kolchinsky and Raj Shah's RA Capital has $461M more to play with, after 'rapid' investment in the last 15 months (Endpoints)
• Promising better linker tech to ADC field, Araris has 'very, very ambitious' plans for the clinic (Endpoints)
• Master dealmaker David Hung retools a SPAC sedan into a financing muscle vehicle that leaves his cancer startup with $850M and a place on Wall Street (Endpoints)

• With Just 7 Notified Bodies Expected By Mid-2021, How Can Companies Prepare For The IVDR? (MedtechInsight)
• Edwards TAVR sales grow 6% but Q4 forecast disappoints (MedtechDive)
• Eyeing big Covid-19 testing expansion, Ginkgo rolls out 50M rapid antigen diagnostics (Endpoints)
• Abbott device growth returns as Wall Street queries staying power of COVID-19 test boom (MedtechDive)
• FDA slates VR for lower back pain and fibromyalgia for expedited review (Mobihealthnews)
• Robotic surgery pricier, with no measurable benefit in hernias: Cleveland Clinic trial (MedtechDive)
• Quest Diagnostics ups guidance, notches major sales growth and gives back CARES Act cash (Fierce)

• Where DOJ's Opioid Blitz Stands After Purdue's Criminal Case (Law360)
• Biden’s Big Health Agenda Won’t Be Easy to Achieve (KHN)
• Pa. Justices OK State's Jurisdiction Over J&J In Mesh Cases (Law360)
• Fed. Circ. Ruling Is Troubling For Generic Drug Manufacturers (Law360)
• DOJ Can Jump Into Teva Suit, But Only On Limited Basis (Law360)